Modeling Spinal Muscular Atrophy in Mouse: A Disease of Splicing, Stability, and Timing by Thomas W. Bebee & Dawn S. Chandler
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
16 
Modeling Spinal Muscular Atrophy in Mouse:  
A Disease of Splicing, Stability, and Timing 
Thomas W. Bebee and Dawn S. Chandler 
The Center for Childhood Cancer at the Research Institute at  
Nationwide Children’s Hospital, Columbus, Ohio; 
The Department of Pediatrics, The Ohio State University, Columbus, Ohio; 
United States of America 
1. Introduction 
Proximal spinal muscular atrophy (SMA) is a progressive neurodegenerative disease 
associated with the loss of alpha motor neurons in the lumbar spinal cord. The loss of these 
motor neurons leads to the progressive atrophy of the associated proximal muscles, 
eventual respiratory distress, and death. SMA occurs in about 1 in 6,000 to 10,000 live births 
and is a leading genetic cause of infant mortality (Burnett et al. 2009). SMA is subdivided 
into several groupings based on disease onset, severity, and outcome. The most severe form 
of SMA is referred to as type 0, or embryonic SMA, wherein patients are born with severe 
muscle atrophy and have expected lifespans of less than 6 months. The most common type 
of SMA is type I, which is characterized by disease onset within 6 months and mortality by 
age 2. Children with SMA type I often fail to sit unaided or walk, have difficulty breathing, 
and often require respiratory assistance. SMA type II children experience disease onset 
between 6 to 18 months and will not gain the ability to walk. Two forms of SMA are 
characterized by disease onset later in life and have unaltered life expectancies: juvenile and 
adult onset SMA, or type III and IV, respectively. Juvenile onset SMA type III is 
distinguished by disease onset after the age of 2, but there is variability of onset that can 
extend to early teen years. Type III children are often able to walk, and the ability to remain 
ambulatory throughout life can further subdivide this juvenile onset SMA. The least severe 
form of SMA is adult onset SMA type IV. This form of SMA does not emerge until the adult 
years and often presents with difficulty in performing previously attainable activities, such 
as climbing stairs (Zerres et al. 1995; Zerres et al. 1997; Zerres et al. 1997). 
In SMA disease progression, the inability to achieve normal motor function is often the 
primary indication of disease. The level of motor function decline in SMA disease 
progression can be measured by the loss of functional motor units in SMA patients. In 
severe forms of SMA, there is a rapid loss of motor neurons innervating proximal muscles. 
This measure of reduced motor units can be observed by evaluating the Compound Motor 
Action Potential (CMAP) and Motor Unit Number Estimation (MUNE). The total number of 
innervated motor units is reduced in SMA disease as measured by these two tests and is 
correlated with age, severity of disease, and disease progression (Swoboda et al. 2005). The 
loss of motor neurons early in the onset of disease argues for the significance of motor 
neurons in disease, although additional components of the disease may provide for the 
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rapid degeneration of SMA patients in late disease. Respiratory weakness is a common 
feature of both severe and milder forms of SMA. Children with type I or II SMA will often 
require respiratory assistance by way of Bi-level Positive Airway Pressure (BiPAP) (Bach et 
al. 2003), just as less severe forms of SMA also exhibit respiratory weakness that may require 
assistive breathing and respiratory therapy. While SMA is most directly associated with 
motor neuron loss, neuronal defects in sensory neurons are also observed in severe SMA 
patients (Rudnik-Schoneborn et al. 2003). A new emerging component of SMA is cardiac 
involvement in a subset of severe SMA patients, such as congenital cardiac defects and 
bradycardia (Bach et al. 2003; Rudnik-Schoneborn et al. 2008). 
2. Genetic cause of SMA, reduced levels of SMN protein 
The decreased level of the crucial Survival Motor Neuron (SMN) protein is the cause of 
SMA disease. The low levels of SMN protein are due to the loss of the essential Survival 
Motor Neuron-1 (SMN1) gene located on chromosome 5q13. SMA patients have lost SMN1 
by mutation or deletion, and the functional loss of SMN1 is the disease locus of SMA 
(Lefebvre et al. 1995). In mice, the loss of the homologous Smn gene results in embryonic 
lethality (Schrank et al. 1997; Hsieh-Li et al. 2000); however, humans carry a duplication of 
the SMN1 gene, SMN2, which encodes the same SMN protein. All SMA patients are 
genetically comprised of SMN1 gene loss (mutation or deletion) with variable copy numbers 
of SMN2 (Lefebvre et al. 1995; Lefebvre et al. 1997; McAndrew et al. 1997). The copy number 
of SMN2 inversely correlates with the severity of SMA, where higher copy numbers of 
SMN2 increase SMN protein and, therefore, decrease the severity of disease (Lefebvre et al. 
1997; McAndrew et al. 1997). SMA patients that have 1-2 copies of SMN2 are often 
associated with severe SMA type I, and SMA patients with higher SMN2 copy number 
exhibit SMA type II-IV (Lefebvre et al. 1997).  
The incomplete compensation for the loss of SMN1 by SMN2 is due to the inefficient 
splicing of the SMN2 pre-mRNA (Lefebvre et al. 1995; Lorson et al. 1999). The altered 
splicing is due primarily to a single silent C>T point mutation in exon 7 that reduces 
recognition of exon 7 by the splicing machinery (Lorson et al. 1999). The functional role of 
the C>T mutation in exon 7 skipping can be explained by two models. The first model 
describes the loss of a putative exon splicing enhancer for SF2/ASF (SRSF1), where reduced 
binding of SF2/ASF (SRSF1) is associated with SMN2 exon 7 skipping (Lorson et al. 2000; 
Cartegni et al. 2002; Cartegni et al. 2006). The second model is explained by the generation of 
an exonic splicing silencer for hnRNP A1 (Kashima et al. 2003; Kashima et al. 2007). Both of 
these models functionally explain the alteration in the recognition of exon 7 via the C>T 
point mutation that generates transcripts lacking exon 7 (∆X7) from SMN2. The complex 
splicing regulation of SMN exon 7 beyond the critical C>T mutation has been recently 
reviewed (Bebee et al. 2010; Singh et al. 2011).  
SMA is a disease associated with reduced splicing efficiency of SMN encoding transcripts. 
Furthermore, the significance of reduced SMN protein in normal cellular maintenance is 
underscored by the importance of SMN in splicing. SMN is crucial for splicing, as the SMN 
protein is the primary scaffolding protein involved in the maturation of the core splicing 
factors, or U snRNPs (Fischer et al. 1997; Liu et al. 1997; Pellizzoni et al. 1999; Meister et al. 
2001; Pellizzoni et al. 2002). The SMN protein, in complex with several other components, 
comprises the SMN complex (Paushkin et al. 2002). The SMN complex loads the heptameric 
Sm ring (Raker et al. 1996) onto the Sm site of U snRNPs, completing the processing of the 
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splicing core components for function in canonical splicing of nascent transcripts (Fischer et 
al. 1997; Liu et al. 1997). In SMA, the SMN protein levels are reduced due to loss of SMN1, 
and the primary product of SMN2 is the SMN∆7 protein produced by the transcripts lacking 
exon 7 (Lefebvre et al. 1995; Lefebvre et al. 1997). The SMN∆7 protein is unstable and 
exhibits reduced protein function (Wang et al. 2001; Cho et al. 2010). However, a portion of 
SMN2 transcripts encode full-length SMN protein sufficient for birth, but insufficient for 
motor neuron maintenance. The ability of SMN2 to generate full-length transcripts provides 
for potential therapeutic intervention by increasing transcription or correcting the splicing of 
SMN2 to increase the pools of SMN to levels consistent with normal development. 
3. Genetic modeling of SMA in mouse 
The duplication event of SMN1 that generated SMN2 occurred late in evolutionary history, 
and thus, mice carry only a single Smn gene homologous to SMN1 (Bergin et al. 1997; 
Rochette et al. 2001). After identification of the gene responsible for SMA disease, efforts to 
model the human disease in mice began by generating null alleles of the mouse Smn gene 
(Summarized in Table 1). Null alleles of the Smn gene were generated by replacing exon 2 or 
7 with reporter cassettes, and from these experiments the Smn gene was found to be essential 
as Smn -/- mice were embryonic lethal at the eight cell stage post fertilization (Schrank et al. 
1997; Hsieh-Li et al. 2000). The requirement of SMN for survival is congruent with the function 
of SMN in maturation of the splicing machinery as an essential function for viability in 
eukaryotes. Mice heterozygous for the Smn null alleles have normal lifespans and do not 
exhibit haploinsufficiency; however, they do develop a mild form of SMA with muscle 
weakness and motor neuron loss later in life (Jablonka et al. 2000; Monani et al. 2000).  
SMA is a disease of reduced SMN protein, and although the loss of Smn represents the loss 
of SMN1 seen in SMA patients, this does not fully model the genetics of SMA. To more 
closely recapitulate the etiology of SMA, bac transgenes that included SMN2 were 
introduced into the Smn null mice (Hsieh-Li et al. 2000; Monani et al. 2000). The SMN2 in the 
bac transgenes exhibit splicing defects similar to SMN2, as exon 7 is primarily skipped and 
low SMN expression is seen. The level of SMN protein generated from the SMN2 transgenes 
was sufficient to correct the embryonic lethality in Smn null mice. The rescue by SMN2 in 
Smn null mice is in accordance with the observation that all SMA patients have SMN2 
present. Moreover, increased copy numbers of SMN2 led to variable severities of SMA that 
stratify human SMA disease. Mice with 2 copies of SMN2 (“Line89”) exhibited severe SMA 
with an average lifespan of 4-6 postnatal days, but an increase of the SMN2 copy number to 
8 rescued the Line89 mice from SMA disease (Monani et al. 2000). Mice generated using a 
second Smn null allele (disruption of Smn exon 7) in combination with an SMN2 bac 
transgene, termed the Taiwanese or Hsieh-Li mice, generated mice that exhibited severe to 
mild SMA. Hsieh-Li mice with 2 copies of SMN2 survived 1 week and mice with 4 copies of 
SMN2 had normal survival but developed peripheral necrosis (Hsieh-Li et al. 2000). A 
simplified crossing scheme of these mice now allows for independent generation of both the 
severe mice that survive 10 days, as well as the mild mice with normal survival (Riessland et 
al. 2010).  
In severe SMA mouse models, reduced SMN protein, loss of anterior horn lumbar motor 
neurons, and muscle atrophy lead to the observed reduction in survival of 6-10 days (Hsieh-
Li et al. 2000; Monani et al. 2000). Interestingly, the lifespan of the severe Line89 mouse was 
extended to PND13.5 by transgenic over-expression of the SMN∆7 transcript (Le et al. 2005).  
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Genotype Phenotype and Notes Shorthand References 
Smn-/- Embryonic lethal at preimplantation  
(8 cell stage). Smn exon 2 knockout. 
Smn 
knockout 
Schrank 
1997 
Smn+/- Grossly normal with normal lifespan in 
the heterozygous Smn exon 2 knockout 
mice. Motor neuron loss in spinal cord: 
40% at 6 months, 54% at 12 months. 
Line89 het 
carrier 
Jablonka 
2000 
Smn-/-; 
SMN2(2Hung)+/+ 
 
Bac transgene (115 kb) including human 
SMN2, SERF1 and part of NAIP genes; 
rescues embryonic lethality of Smn-/- 
(HPRT knockout of Smn exon 7). 
Variable SMN2 copy number, with 
increasing copy number lessening 
disease severity (Type I-III). 
Taiwanese 
or Hsieh-Li
Hsieh-Li 
2000 
Smn-/-; 
SMN2(89Ahmb)+/+ 
 
Transgene containing SMN2 (35.5 kb); 
rescues Smn-/- (exon 2 null allele) 
embryonic lethality. 2 copies of SMN2 
in the mice have severe SMA and die 
postnatally with mean survival PND4-6. 
Motor neuron loss PND5. Eight copies 
of SMN2 rescue SMA phenotype. 
Line89 Monani 2000 
SmnF7/∆7; NSE-Cre 
 
Cre-mediated Smn exon 7 excision in 
neurons. Mice develop a SMA like 
pathology with progressive motor 
neuron loss (cell body number and axon 
number) in the lumbar spinal cord, 
muscle atrophy, and have a mean 
survival of 25 days. 
F7 or exon 
7 floxed  
Frugier 2000, 
Cifuentes-
Diaz 2002 
SmnF7/∆7; HSA-Cre 
 
Cre-mediated Smn exon 7 loss in 
skeletal muscle. Muscle cell death and 
dystrophy-like pathology, with a mean 
survival of 33 days. 
F7 or exon 
7 floxed  
Cifuentes-
Diaz 2001 
Smn-/-; 
SMN2(89Ahmb)+/+; 
SMN1(A2G)+/- 
 
Heterozygous expression of SMN1 A2G 
patient mutation transgene increase 
survival of Line89 mice to ~227 days, 
but is dependent upon SMN2 (2 copies). 
Reduced motor neuron number in 
spinal cord (29%) and facial nucleus 
(19%) at 3.5 months. ~25% reduction in 
spinal motor axon by 5 months, muscle 
atrophy, and axonal sprouting in 
gastrocnemius and triceps. 
Homozygous A2G are phenotypically 
normal. 
A2G 
 
Monani 2003 
Table 1. Mouse models of SMA. (continues on next page) 
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Genotype Phenotype and Notes Shorthand References 
SmnF7/F7; Alfp-Cre Cre-mediated Smn exon 7 excision in 
hepatocytes is embryonic lethal at E18.5.
F7 or exon 
7 floxed 
Vitte 2004 
Smn-/-; 
SMN2(89Ahmb)+/+; 
SMN∆7+/+ 
Expression of the SMN∆7 transgene in 
Line89 mice extend survival to ~13.5 
days. Motor neuron loss by PND9, 
weight and motor deficits, and muscle 
atrophy. 
SMN∆7 
 
Le 2005 
Smn-/-; 
SMN2(89Ahmb)+/+; 
SMN1(A111G)+/- 
Transgene of SMN1 A111G patient 
mutation rescues Line89 mice. Survival 
is normal but requires SMN2 (2 copies). 
Gastrocnemius muscle hypertrophy at 
10 months and rescued the deficits in 
snRNP assembly seen in the Line89 
mice. 
A111G Workman 
2009 
Smn2B/- Mutation of exonic enhancer in Smn 
exon 7 leads to low Smn protein levels 
and mean survival of 28 days. Muscle 
weakness and atrophy, and reduced 
motor neurons at PND21. 
2B Bowerman 
2009, 
Bowerman 
2010 
Smn-/-; 
SMN2(N11)+/-; 
SMN2(N46)+/- 
Mice with three copies of SMN2 from 
N11(one copy) and N46 (two copies) 
alleles have a mean survival of 14-16 
days. Muscle atrophy and motor neuron 
loss by PND15. Respiratory deficits and 
NMJ defects in diaphragm. 
3 copy 
SMN2 
Michaud 2010 
SmnF7/-; 
SMN2(89Ahmb)+/+; 
Olig2-Cre 
Cre-mediated Smn exon 7 excision in 
motor neuron progenitor cells that also 
express basal SMN from SMN2. 70% 
survival to 12 months, motor neuron 
loss in spinal cord, muscle atrophy, and 
reduced sensory neuron innervation 
and number in DRG. 
Olig2-Cre 
SMA 
Park 2010 
SmnC>T Smn gene carrying the SMN2 exon 7 
C>T mutation induces exon 7 skipping 
and reduces Smn protein. Mild SMA 
disease onset at 60 days associated with 
hind limb weakness, reduced activity 
and rearing, and muscle hypertrophy in 
gastrocnemius. Normal survival. 
Smn C>T Gladman 
2010 
Table 1. (continued) Mouse models of SMA 
The mechanism of life extension in this severe SMA mouse model is not easily understood 
but begs the question of whether the SMN∆7 protein has a functional role in normal 
development and/or neuroprotection. Another transgene that modified the survival of the 
severe Line89 mice is the SMN1 A2G mutation. The A2G transgene alone was unable to 
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rescue the Smn null mice; however, survival extension through expression of the A2G 
transgene was contingent upon expression of SMN from the SMN2 transgene. The 
transgenic A2G mouse develops mild SMA early in life, though survival is near 1 year and 
the mice with SMA pathology can appear normal until disease progression late in life. The 
A2G mice are associated with motor neuron defects such as motor neuron loss, branching, 
neurofilament accumulation, and failure to respond to repeated stimuli (Monani et al. 2003; 
Kariya et al. 2008). The milder SMA phenotype may be explained by the partial ability of the 
A2G mutant SMN protein to bind to normal full-length SMN. This binding is greater than 
that of the SMN∆7 protein, arguing the potential for partial rescue of SMN complex 
formation in the A2G SMA mouse model (Monani et al. 2003). 
SMA mouse models that carry the SMN2 gene can be used to evaluate the expression and 
splicing of SMN2 in tissues otherwise inaccessible in SMA patients, such as the central 
nervous system (CNS). Furthermore, the effect of disease progression and therapies 
targeting correction of SMN2 can also be evaluated in mice that have the SMN2 bac 
transgenes. The short lifespan of the severe SMA mouse models also allows for rapid 
evaluation of treatments aimed at increasing SMN, as changes in survival can readily be 
addressed in the short-lived mice. However, the short lifespan of these SMA models does 
not allow for therapeutic intervention at later time-points in development and SMA disease. 
Further attempts to modulate the lifespan of the severe SMA by simply titrating the copy 
number of SMN2 in mice have proven difficult. One group generated two SMN2 transgenic 
lines that harbor 1 or 2 copies of SMN2 per allele (lines N11 and N46). When combined to 
generate a 3 copy SMN2 mouse, the survival was extended to PND14-16 with some outlier 
longer lived mice (Michaud et al. 2010). This average survival is similar to the SMN∆7 mice 
and is accompanied by severe muscle weakness and atrophy late in disease, motor neuron 
loss by PND13, abnormal EMG, and NMJ defects. These mice also exhibit respiratory 
deficiencies associated with reduced volume and frequency. Additional allelic series of mice 
have been generated harboring alterations in the Smn gene and SMN hybrid alleles to titrate 
SMN protein levels in mice (These mice can be found on the Jackson Laboratories web site 
http://jaxmice.jax.org/list/ra1733.html). 
Successful generation of SMA mouse models was achieved through the loss of Smn protein 
using Smn null alleles in combination with transgenic expression of SMN from SMN2 and 
other SMN transgenes. However, to simplify the genetics of modeling SMA in mice, it 
would be desirable to place both the gene loss and modifier expression in the same locus. 
The cosegregation of these two genetic events would allow for regulation of transcription 
and splicing in the endogenous genetic locus. The Smn C>T allele was engineered by 
introducing the SMN2 exon 7 C>T mutation in the murine Smn gene. The Smn C>T mouse 
mimics the genetics of SMA patients, and recapitulates the splicing defect of SMN2, wherein 
exon 7 is skipped due to the C>T mutation. These mice exhibit reduced total Smn protein 
and a mild SMA phenotype characterized by hind limb weakness and inactivity consistent 
with type III SMA (Gladman et al. 2010). A second Smn C>T allele has been engineered (Smn 
C-T-Neo); however, this allele harbors the exon 7 C>T mutation with the neo cassette in 
intron 7 and additional sequences at the 5’ end of exon 8. The splicing pattern of this mouse 
allele is primarily exon 7 skipped transcripts, and as such, produces very low Smn protein 
levels leading to embryonic lethality. The Smn C-T-Neo mouse has been used as an 
inducible Smn allele as the low Smn protein levels can be increased by the removal of the 
neo cassette; however, this must be done early in embryonic development (E7.5) or the 
embryo will be resorbed (Hammond et al. 2010).  
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Type I
Type I-II
1 2 3 4 5 6 7 8
I: Line89
II: SMN฀7; Hsieh-Li (2
copy SMN2), 3 copy SMN2
weeks
12 18 24
III-IV: A2GType III
months
6
SMA Mouse Models
Type III-IV III-IV: Smn +/-, Smn C>T,
Hsieh-Li (4 copy SMN2)
 
Fig. 1. SMA mouse models: survival and disease onset. Graphical representations of mean 
survivals of SMA mouse models types I-IV are shown by grey bars. Time scale is in weeks  
0-8 and in months 6-24. A red line indicates the disease onset of SMA phenotype. For the 
mild SMA mouse models, a red-hashed box indicates variable onset in the listed SMA 
mouse models (i.e.: Smn +/- is 6 months, Smn C>T is 8 weeks, and Hsieh-Li (4 copy SMN2) 
has tail necrosis starting at 4 weeks) 
Mutations in the mouse exon splicing enhancer for Tra2beta (2B) in exon 7 produces high 
levels of skipped transcripts in the absence of the C>T mutation (DiDonato et al. 2001). The 
mutation in the Tra2Beta enhancer is not associated with SMA mutations, and though it 
does induce exon 7 skipping, it does not recapitulate the splicing defect of SMN2. A mouse 
with the Tra2beta mutation in Smn (Smn2B-Neo) has low Smn protein levels that are 
associated with reduced size at two weeks, a lifespan of one month, and motor neuron loss 
late in disease progression (Bowerman et al. 2009; Bowerman et al. 2010). Smn alleles that 
genetically simplify and model SMA disease provide for evaluation of Smn protein 
reduction in SMA disease progression and can be used in evaluating therapeutic regimes for 
SMA. In choosing the appropriate mouse model to test therapeutics the survival and disease 
onset will be crucial considerations (graphically represented in Fig. 1). 
4. Addressing the tissue specificity and timing of SMN expression in mouse 
models of SMA 
The requirement for SMN expression in survival and motor neuron maintenance was 
evident in the genetic modelling of SMA in mice. However, the spatial and temporal 
requirement for SMN expression in tissues affected by SMA was not initially evaluated. To 
evaluate the requirement of SMN in specific tissues for SMA disease pathology, the deletion 
(Table 1) and expression of SMN in specific tissues (Table 2) has been tested in mice. An 
inducible Smn allele in which exon 7 is flanked by loxP sites (F7 allele) can replicate the loss 
of exon 7 (Frugier et al. 2000). This model has been utilized to knockout Smn exon 7 in a 
variety of tissues such as neurons, muscles, and liver by tissue specific Cre expression. The 
removal of exon 7 by Cre recombinase is irreversible and is associated with cell death in the 
target tissue being tested (Frugier et al. 2000; Cifuentes-Diaz et al. 2001; Vitte et al. 2004). The 
loss of full-length SMN through use of the inducible F7 Smn allele in neurons lead to 
neuronal cell death and mice exhibiting SMA pathology associated with motor neuron loss, 
whereas loss in muscle leads to a muscular dystrophy-like phenotype in the absence of 
motor neuron loss (Frugier et al. 2000; Cifuentes-Diaz et al. 2001). In an inverse experiment, 
increased expression of SMN was isolated to either neurons or muscle by tissue specific 
promoters in the severe Line89 mice. Rescue of the SMA phenotype was observed in 
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neuronal expression of SMN whereas muscle expression did not rescue the SMA disease 
(Gavrilina et al. 2008). Together, these studies argue that the expression of SMN is a 
requirement for basic cellular maintenance and that SMN expression in neurons can rescue 
the SMA phenotype.  
The targeted excision of Smn exon 7 (F7) can remove Smn protein rather than reduce the 
levels, as is seen in SMA patients. To recapitulate the reduced levels of SMN protein, the F7 
targeted deletion was used in motor neuron progenitor cells in conjunction with low levels 
of SMN generated by two copies of the SMN2 transgene. SMN reduction restricted to motor 
neuron precursors resulted in a mild SMA pathology, survival rate of 70% at one year, 
reduced weight and muscle mass, and central and peripheral nerve dysfunction. This study 
reports a direct effect of reduced SMN protein levels in motor neurons leading to SMA 
pathology in mice. The reduced severity of SMA may be explained by the presence of 
normal levels of SMN in other cell types, which would also have reduced SMN protein 
levels in SMA disease (Park et al. 2010). 
The evaluation of SMA mouse models has elucidated changes that occur early and late in 
disease progression. Thus, the timing of SMN replacement in disease may alter the therapeutic 
benefit of SMN replacement for disease correction. This consideration has been addressed in 
severe SMA mouse models in both genetic and therapy based experiments. Most drug 
treatment regimes require early administration to allow for survival extension and 
improvement of phenotype in severe mouse models of SMA, including prenatal treatment 
for Line89 mice (Riessland et al. 2010). Gene therapy using scAAV9 SMN expression argues 
that early postnatal expression of SMN in motor neurons is required for survival extension, 
with the greatest success at PND1. However, the rescue observed by systemic delivery of the 
viral vector required transduction of motor neurons in the CNS (Foust et al. 2010; Valori et 
al. 2010; Dominguez et al. 2011). Accordingly, the inability to rescue survival at later time-
points may be a result of limited access to the CNS by the maturation of the blood brain 
barrier. The use of RNA molecules that mediate splicing correction can extend survival 
when administered early postnatally as well (Baughan et al. 2009; Coady et al. 2010; Passini 
et al. 2010). The ability of each of these therapeutic modalities requires access to the CNS 
and motor neurons for effective therapeutic benefit in SMA mouse models.  
The use of genetic models of induced SMN expression can bypass the limitation of other 
therapeutic strategies to determine the therapeutic window in SMA mouse models. Genetic 
induction of Smn from embryonic lethal Smn hypomorphic alleles can prevent early 
embryonic lethality when induced early in utero (E7.5) (Hammond et al. 2010). Recently, 
genetic induction of SMN expression using a high expressing doxycycline inducible SMN 
transgene showed similar survival extension in the severe SMN∆7 mice, comparable to that 
of scAAV9 SMN treatment (Foust et al. 2010; Le et al. 2011). In the doxycycline inducible 
SMN model, induction in embryos (E13.5) had the greatest survival extension to over 200 
days, whereas neonatally treated (PND0-3) SMN∆7 mice survived 86 days. Interestingly, the 
removal of doxycycline (i.e.: SMN over-expression ceased) at weaning (28 days) did not lend 
to rapid decline or death, arguing that lower levels of SMN expression may be sufficient 
later in life (Le et al. 2011). Together, these data argue for the requirement of early postnatal 
expression of SMN for therapeutic benefit in severe SMA mouse models, and SMN 
expression in motor neurons is required for considerable increase in mean lifespan. A still 
unresolved question is whether the same timing of SMN replacement will be required for 
treatment in milder SMA mouse models, or if a later therapeutic window exists. Some 
evidence offers that late treatment in mild SMA may be beneficial as the use of ASOs that 
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correct SMN2 splicing in the Hsieh-Li (4 copy SMN2) mouse can reduce tail necrosis seen in 
these mice (Hua et al. 2010). 
 
Genotype Phenotype and Notes Shorthand References 
Smn-/-; 
SMN2(89Ahmb)+/+; 
PrP92-SMN+/+ 
SMN expression in neurons 
under the prion promoter (PrP) 
recues disease in Line89 mice. 
Neuronal 
SMN 
Gavrillina 2008 
Smn-/-; 
SMN2(89Ahmb)+/+; 
HAS63-SMN+/+ 
SMN expression in muscle under 
the human skeletal actin (HAS) 
promoter does not rescue SMA 
disease in Line89 mice. Leaky 
expression in neurons can afford 
moderate rescue in Line89 mice. 
Muscle SMN Gavrillina 2008 
Smn-/-; 
SMN2(89Ahmb)+/+; 
SMN∆7+/+; 
ROSA26rtTA+/+; 
Luci-TRE-SMN+/+ 
Induction of SMN expression by 
doxycycline within 3 days. 
Embryonic (E13) and PND0 
treatment extend survival, mean 
100 days but can extend to 200 
days, and corrects NMJ defects. 
Removal of doxycycline at 28 
days exhibits continued survival 
and rescue of NMJ defects. 
Doxycycline 
Inducible 
SMN 
Le 2011 
SmnC-T-Neo/C-T-
Neo;CreEsr1 and 
Smn2B-Neo/2B-
Neo;CreEsr1 
Tamoxifen induced Cre-
mediated excision of the 
neomycin cassette alters the 
hypomorphic C-T-Neo and 2B-
Neo alleles from ~5% SMN to 
~30% and 16%, respectively. 
Early (E7.5) tamoxifen treatment 
can rescue to embryonic lethality 
and resorption of the C-T-Neo 
mouse early in embryonic 
development, though the ability 
to rescue animals to birth has not 
been shown. 
Inducible Smn 
hypomorphic 
alleles 
Hammond 2011 
Smn +/+; Tg SMN2; 
CreERT2 
Inducible SMN expression is 
under control of tamoxifen 
inducible Cre (CreERT2). 
Tamoxifen administration in 
embryonic (E13.5), neonatal 
(PND1.5), and weanling (4 week 
old) mice induces SMN 
expression. Ability to rescue 
survival has not yet assessed in 
SMA mouse models.  
Tamoxifen 
Inducible 
SMN 
Bebee 2011 
Table 2. Inducible SMN mouse models 
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5. SMN snRNP function and splicing in SMA mouse models 
The best-characterized function of SMN is the maturation of the core snRNPs required for 
splicing (Fig. 2). To test the effect of reduced SMN levels on snRNP assembly in SMA, the 
maturation of both major (U2) and minor (U12) snRNPs were assessed in severe Line 89 
mice. In these severe mice, the reduction of SMN protein correlated with reduced 
maturation of a subset of snRNPs, especially the minor spliceosomal pathway U11 and U12 
snRNPs (Gabanella et al. 2007). In the SMN∆7 mice, reduced U4 snRNP maturation was also 
reduced in the brain and kidney. The relative levels of snRNAs in the SMN∆7 mice were 
altered in disease progression, with the minor spliceosome again showing the greatest 
reduction at PND11 in the SMA mouse models (Zhang et al. 2008). To genetically evaluate 
perturbations of snRNP assembly in SMA disease, a transgene of the mild SMA mutation in 
SMN1 (A111G) was expressed in Line89 mice. Expression of the A111G transgene extended 
survival to a normal lifespan with no observable phenotype, though the A111G mice 
showed signs of muscle hypertrophy in the gastrocnemius at 10 months of age. The survival 
extension was SMN2 dependent as A111G failed to rescue the Smn -/- mice alone, arguing 
  
 
Fig. 2. SMN function in motor neurons. Normal and SMA motor neurons are depicted with 
blue shading corresponding to SMN protein levels. The SMN complex (blue oval) loads the 
Sm core (red circle) onto the Sm site (red box) of U snRNAs. In normal motor neurons 
sufficient SMN is present to form the mature U snRNPs, whereas SMA motor neurons lack 
sufficient SMN to mature all U snRNAs. Reduced SMN leads to motor neuron loss and 
dysfunction, which can be seen by immaturity of the NMJ and eventual loss of motor 
neurons by retraction of the axonal processes and cell death. While U snRNP maturation is 
the primary function of SMN, other functions of SMN in the axon or at the NMJ may still 
contribute to SMA pathology 
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for intragenic complementation between the SMN from SMN2 and the mutant A111G SMN 
protein. Analysis of snRNP assembly in the severe Line89 mice also showed reduced U4 and 
minor spliceosomal snRNP maturation that was subsequently rescued by the expression of 
the A111G transgene (Workman et al. 2009). 
The impact of SMN reduction in mice leads to reduced maturation and relative levels of 
snRNAs during SMA disease progression. The impact of the alteration in the maturation of 
the core splicing machinery on splicing in SMA disease was addressed in the severe mouse 
models of SMA at early and late stage disease. Evaluation of SMN∆7 mice prior to disease 
(PND1) and early in disease (PND7) did not show differences in splicing, but later in disease 
progression (PND11 and 13), global splicing changes were observed using a splicing 
sensitive microarray (Zhang et al. 2008; Baumer et al. 2009). Major changes in splicing of 
neuronal and cellular damage genes were observed (Baumer et al. 2009). In the more severe 
Line89 mice, gene expression analysis in PND1 mice did not show major expression changes 
in the presymptomatic mice. However, genes involved in extracellular matrix, myelination, 
and cellular growth factors showed major changes in late disease progression at PND5 
(Murray et al. 2010). These observations set SMA as a global splicing disease late in disease 
progression, which may account either for the effect of cellular stress on global splicing or a 
global alteration in snRNPs that contribute to disease in mouse models of SMA. While the 
importance of SMN protein in other non-snRNP associated neuronal functions in still under 
evaluation, it is clear that the reduction of SMN directly correlates with reduced maturation 
of snRNPs. As SMN2 is itself improperly spliced, the potential for reduced exon 7 inclusion 
when SMN is low was evaluated using in vitro splicing assays. Extracts prepared from cells 
expressing low levels of SMN reduced inclusion of SMN exon 7, implicating a negative 
feedback loop effect of low SMN protein levels on exon 7 inclusion. This could be associated 
with the weak definition of exon 7, making the SMN transcript more susceptible to low 
levels of mature snRNPs required for canonical splicing (Jodelka et al. 2010). 
6. Neurological manifestations in SMA mouse models 
SMA is a disease of motor neurons, and as such mouse models of SMA have been evaluated 
for both the loss of motor neurons in the development of SMA disease, as well as other 
neurological manifestations in the SMA mouse models. Neuronal evaluation of the SMA 
mouse models has uncovered the timing of motor neuron loss and populations of neurons 
affected in the SMA mice. The neurological manifestations and major findings in the SMA 
mouse models have been outlined below.  
The loss of motor neurons in SMA as observed in SMA patients was the first neuronal cell 
types evaluated in models of SMA mice. Histological analyses of motor neuron populations 
in the spinal cord of SMA mouse models have demonstrated that the loss of motor neurons 
is also seen during the progression of the disease in mice. Surprisingly, the loss of motor 
neurons in the spinal cord is a late marker of disease, occurring after a motor deficit is 
already observed and late in disease progression (Hsieh-Li et al. 2000; Jablonka et al. 2000; 
Monani et al. 2000; Monani et al. 2003; Le et al. 2005; Avila et al. 2007; Kariya et al. 2008; 
Bowerman et al. 2009; Michaud et al. 2010; Park et al. 2010; Riessland et al. 2010). The 
development of motor neurons was thus further analysed in the most severe mice (Line 89) 
during embryonic and neonatal development. In the Line89 mice the neuronal pathfinding 
and development of motor neurons appears normal in this SMA mouse model, although 
some abnormal axonal swelling were more pronounced in the SMA mouse model compared 
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to control littermates (McGovern et al. 2008). The presence of motor function deficits in the 
SMA mouse models prior to motor neuron loss raised the question of whether motor neuron 
function was compromised. To evaluate the function of the motor neurons, both anatomical 
and electrophysiological analyses have been performed in severe and mild SMA mouse 
models. In severe and mild models of SMA, accumulation of neurofilament in the presynaptic 
termini of motor neurons, disorganization of the postsynaptic NMJ, reduced synaptic vesicle 
release, and motor neuron sprouting have been reported (Cifuentes-Diaz et al. 2001; Monani 
et al. 2003; Kariya et al. 2008; McGovern et al. 2008; Murray et al. 2008; Kong et al. 2009; Ling 
et al. 2010; Michaud et al. 2010; Park et al. 2010; Lee et al. 2011). The changes at the NMJ are 
also associated with expression of immature isoforms of both the acetylcholine receptor 
(AChR) and myosin heavy chain (MyHC) (Kariya et al. 2008; Lee et al. 2011). The loss of 
motor neurons and changes in expression of genes involved in myelination, growth factor 
signalling, and extracellular matrix are associated with late stage of disease in SMA mouse 
models (Murray et al. 2010). The susceptibility of motor neurons holds true from mouse to 
human, in addition the susceptibility can also differ in subpopulations of motor neurons in a 
single muscle such as the levator auris longus (LAL) muscle (Murray et al. 2008; Murray et 
al. 2010; Ruiz et al. 2010). 
The defects observed in motor neuron function followed by loss of motor neurons late in 
disease raised the question of whether other neuronal populations were affected in the 
SMA mouse models. Defects in sensory neurons have been reported in SMA patients 
(Rudnik-Schoneborn et al. 2003), and the 3 copy SMN2 mouse also exhibited latency in 
response to heat (Michaud et al. 2010). The potential for sensory neuron malfunction in 
SMA was further evaluated in the SMN∆7 mouse model. A reduction in the input of 
sensory neurons to the motor neurons of the spinal cord as well as perturbation of the 
neuronal circuitry was evident as early as PND4 in the SMN∆7 mice (Ling et al. 2010; 
Mentis et al. 2011). Furthermore, the reduction of sensory input into lumbar motor neurons 
was also observed in the Olig2-Cre mouse even when the sensory neurons did not have 
reduced SMN protein (Park et al. 2010). The reduction of SMN protein also has 
consequences for neuronal growth and development as evidenced by reduced neuronal 
numbers in the brain and eye of severe SMA mouse models Line89 and Smn 2B (Liu et al. 
2010; Wishart et al. 2010). The modelling of SMA in mice have recapitulated the motor 
neuron loss as is seen in SMA patients, as well as identified neuronal populations affected 
by reduced SMN levels in the SMA mouse models. 
7. Cardiac and pulmonary involvement 
Reports of cardiac defects including congenital heart defects, bradycardia, left ventricular 
cardiomyopathy, and sympathetic-vagal imbalance have recently been reported in severe 
SMA mouse models (Bevan et al. 2010; Heier et al. 2010; Shababi et al. 2010). Evaluation of 
63 severe SMA type I patients reported that 24% presented with severe bradycardia (Bach 
2007). In the severe SMN∆7 mouse model bradycardia was also present due to reduced 
autonomic innervation, and in turn increased vagal tone. Anatomical analysis of SMN∆7 
mice hearts was positive for dilated cardiomyopathy and reduced contractile function 
(Bevan et al. 2010; Heier et al. 2010). Therapies aimed at increasing SMN protein by 
treatment with scAAV9 SMN or TSA were able to improve heart function and survival in 
the treated SMN∆7 mice (Bevan et al. 2010; Heier et al. 2010). A third group reported 
congenital defects present in the severe Line89 mice in the left ventricular septum and wall, 
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but these abnormalities were not observed in the SMN∆7 mice. However, fibrotic 
deposition and oxidative stress markers accumulated in the SMN∆7 heart as disease 
progressed (Shababi et al. 2010). The collective effect of changes in the heart of SMA 
models decreases the functional output and implicates additional neuronal targets by way 
of autonomic neuronal dysfunction in SMA mouse models. As cardiac involvement has not 
been reported in most severe SMA patients, further analysis of patients to identify cardiac 
defects will be required to determine if cardiac treatment is a consideration for SMA 
patients.  
Respiratory complications are common during SMA disease progression and are often 
associated with mortality in severe SMA. Long-term respiratory treatment is often 
requirement in both severe and mild SMA patients. The 3 copy SMN2 mice appear normal 
at PND1 but have reduced numbers of innervated NMJ in the diaphragm at PND9, 
associated with reduced respiratory capacity starting at PND7 (Michaud et al. 2010). Similar 
structural defects at the NMJ in the diaphragm of SMA type I patients have also been 
reported (Kariya et al. 2008). Analysis of the most severe SMA mouse model (Line89) from 
E10.5 to PND2 for motor neuron developmental defects showed the diaphragm was not 
affected; however, intercostal muscle denervation was observed (Kariya et al. 2008; 
McGovern et al. 2008). The defects in motor neurons of the diaphragm and intercostal 
muscles may account for respiratory deficiency in mouse models of SMA, and may be a 
point of therapeutic intervention in SMA patients. 
8. Therapeutic approaches in SMA treatment 
The severity of SMA is directly associated with low SMN protein levels, thus the 
reintroduction of SMN would predict correction of the disease. The presence of SMN2 in all 
SMA patients provides for a direct therapeutic target to increase SMN levels. Therapeutic 
approaches for increasing transcriptional activity of SMN2, splicing correction of SMN2 
exon 7, or stability of SMN protein are major considerations in development of SMA 
therapies. Additionally, increasing SMN levels by gene therapy or treating the disease 
pathology in an SMN independent manner are alternative approaches in SMA therapeutic 
development. Mouse models of SMA have enabled the evaluation of these therapeutic 
approaches in pre-clinical therapeutic regimes for treatment of SMA. 
Small molecules or drugs were the first therapies evaluated for treatment of SMA in mouse 
models of SMA. Many of the initial drugs are FDA approved drugs and transcriptional 
activators, histone deacetylase (HDAC) inhibitors. These drugs increased SMN levels by 
transcriptional activity, splicing of SMN2 exon 7, and/or SMN protein stability (Chang et al. 
2001; Avila et al. 2007; Mattis et al. 2008; Narver et al. 2008; Tsai et al. 2008; Riessland et al. 
2010; Mentis et al. 2011). Additional drugs have been used that target increased stability of 
SMN, read through of SMN2 transcripts, incorporation of SMN2 exon 7, as well as second-
generation drugs that work via multiple mechanisms (Garbes et al. 2009; Hastings et al. 
2009; Butchbach et al. 2010). These drugs improved SMN protein levels and SMA 
phenotype, and often the extension of survival observed in treatment of severe SMA mouse 
models was 30%. However, in current clinical trials in SMA patients, these therapies have 
proven ineffectual (Chen et al. 2010). 
Drug correction of SMN2 splicing underscores the importance of targeting the correction of 
SMN2 splicing as a mode for increased SMN expression. The use of RNA based therapies 
aimed at increasing exon 7 inclusion can be achieved by sequestering a negatively acting 
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sequence in the pre-mRNA and preventing it negative function (Singh et al. 2006; Hua et al. 
2007; Williams et al. 2009; Hua et al. 2010; Passini et al. 2010), recruiting positively acting 
splicing factors to exon 7 (Baughan et al. 2009; Meyer et al. 2009; Voigt et al. 2010), blocking 
exon 8 inclusion (Dickson et al. 2008), or providing an RNA substrate used in the splicing 
reaction (trans-splicing) (Coady et al. 2010). These techniques have successfully increased 
exon 7 inclusion and SMN levels, and have improved survival and phenotype in SMA 
mouse models. 
To reintroduce SMN, viral gene therapies that encode SMN can correct disease if SMN is 
expressed in the appropriate tissues and cell types. Self-complimentary adeno-associated 
virus serotype 9 (scAAV9) can transduce motor neurons in mice when administered early 
postnatally, and the expression of SMN in motor neurons can reduce disease pathology, as 
well as extend survival in the SMN∆7 mouse model (Foust et al. 2010; Valori et al. 2010; 
Dominguez et al. 2011). The requirement for early expression of SMN using scAAV9 argues 
that SMN is required early postnatally for disease correction. However, the ability of the 
viral treatment to reach the spinal cord and motor neurons was reduced after PND5. The 
early therapeutic window outlined by scAAV9 treatment likely represents a limitation of 
viral gene therapy, and does not necessarily reflect the therapeutic window for SMN 
replacement. 
Most SMA patients present with disease after motor neuron loss and motor function has 
already occurred. Treatment of the disease pathology may afford therapeutic intervention 
even in the absence of altering SMN levels. Cell based therapies to replace the lost motor 
neurons have initially been tested by transplanting normal cells that were programmed to 
mature into motor neurons. These cells were injected in the spinal cord, engrafted in the 
spinal cord, and can improve function and survival in the SMN∆7 mice (Corti et al. 2008). 
Furthermore, increasing muscle mass by inhibiting myostatin with the antagonist follistatin 
can reduce muscle loss and improve function and survival, though transgenic overexpression 
of follistatin in SMN∆7 mice failed to improve the survival of the mice (Rose et al. 2009; 
Sumner et al. 2009). As therapeutic development for SMA continues, the use of SMA mouse 
models will continue to be instrumental in pre-clinical testing of therapies for SMA. 
9. Summary and conclusion 
The modeling of SMA in mice has successfully recapitulated many components of SMA 
pathology associated with reduced levels of SMN protein. The use of these SMA mouse 
models has proven invaluable in further understanding the etiology of SMA disease, 
uncovering the neurological manifestations of SMA disease, and the importance of when 
and where SMN expression is required for correction of SMA pathology in mice. The use of 
mouse models of SMA to determine the pathological manifestations in SMA and testing 
therapeutic approaches continues as the need for therapies for this devastating disease 
remains. 
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